Bolt Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
BOLT$6.43-1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(69,197) | $(88,098) |
| Adjustments to reconcile net loss to net cash used | ||
| in operating activities: | ||
| Depreciation and amortization | 1,854 | 1,666 |
| Stock-based compensation expense | 9,223 | 9,576 |
| Accretion of premium/discount on short-term investments | (4,493) | 184 |
| Non-cash lease expense | 2,952 | 3,225 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (454) | (903) |
| Accounts payable and accrued expenses | (3,413) | 2,768 |
| Operating lease liabilities | (2,392) | (2,596) |
| Deferred revenue | (3,606) | (2,162) |
| Other long-term liabilities | 1 | (164) |
| Net cash used in operating activities | (69,525) | (76,504) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (206) | (1,953) |
| Purchases of marketable securities | (164,988) | (180,704) |
| Maturities of marketable securities | 236,232 | 240,519 |
| Net cash provided by investing activities | 71,038 | 57,862 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock | 253 | 503 |
| Net cash provided by financing activities | 253 | 503 |
| NET INCREASE (DECREASE) IN CASH | 1,766 | (18,139) |
| Cash, cash equivalents and restricted cash at beginning of year | 10,809 | 28,948 |
| Cash, cash equivalents and restricted cash at end of period | $12,575 | $10,809 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $10,810 | $9,244 |
| Restricted cash | 1,765 | 1,565 |
| Total cash, cash equivalents and restricted cash | $12,575 | $10,809 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $152 | $8 |
| Deferred offering costs in accounts payable and accrued liabilities | $102 | $102 |
| Right of use assets obtained in exchange for operating lease obligations | $— | $852 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.